Skip to main content

Ibane Abasolo Olaortua

I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module.

Institutions of which they are part

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Biologist
Bioquímica
Cross-departmental services

Ibane Abasolo Olaortua

Institutions of which they are part

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Biologist
Bioquímica
Cross-departmental services

I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module.

I graduated in Biochemistry and Biology at the University of Navarra. During my doctorate in the laboratories of Dr. Alfonso Calvo (CIMA, Pamplona) and Prof. Zhou Wang (Northwestern University, Chicago, USA), I studied the role of a peptide hormone, adrenomedullin, in cancer. Later, I continued my postdoctoral training in the group of Prof. F.X. Real (IMIM, Barcelona), where I acquired extensive experience in experimental mouse models, from the generation of transgenic models to their molecular characterization, an experience that I completed with a specialization in molecular imaging techniques at the IAT-PRBB.
Since 2007, I have been working at Vall d'Hebron, where I started as a post-doctoral researcher and head of the technology platform called Functional Validation & Preclinical Research (FVPR)-U20 ICTS. Since 2021 I am also the leader of the Drug Delivery & Targeting group at VHIR and at the CIBER for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).
My research, and that of my group, seeks to improve the treatment of different diseases through the use of nanoparticles and hydrogels. These systems are specifically designed to protect the therapeutic agent and cause it to be released where and when it is needed. Noteworthy, we work at all steps of the preclinical development, from the design of the nanomaterial, to its synthesis, characterization and testing in experimental models of the disease.
I am currently leading two European projects (SafeNMT and Mimic-key) and two Spanish projects (PI21/00930 and NanoDireCT), focused on the treatment of cancer (breast, pancreas and prostate) and lysosomal storage diseases (Fabry, Sanfilippo and pycnodysostosis).

Projects

Vesículas extracelulares para el tratamiento de enfermeades lisosomales (Título provisional)

IP: Ibane Abasolo Olaortua
Collaborators: Laura García Latorre, Guillem Pintos Morell, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad
Funding agency: Instituto de Salud Carlos III
Funding: 153670
Reference: PI21/00936
Duration: 01/01/2022 - 31/12/2024

Design of Nanoparticles for Blood-Brain-Barrier Crossing and Glioblastoma Multiforme Cancer Stem Cells Targeting (NanoGlio)

IP: Ibane Abasolo Olaortua
Collaborators: Fernanda Raquel Da Silva Andrade, Miriam Izquierdo Sans
Funding agency: Asociación Española Contra el Cáncer
Funding: 100000
Reference: INVES211530DASI
Duration: 01/09/2021 - 31/08/2025

MIMIC-KeY - A KEY TO THE RATIONAL DESIGN OF EXTRACELLULAR VESICLES-MIMICKING NANOPARTICLES.

IP: Ibane Abasolo Olaortua
Collaborators: Joaquin Seras Franzoso, Guillem Pintos Morell, Zamira Vanessa Diaz Riascos, Simon Schwartz Navarro
Funding agency: EUROPEAN COMMISSION
Funding: 457250
Reference: MIMIC-KEY_H2020-FETPROACT-2020
Duration: 01/06/2021 - 31/05/2025

Vehiculización de proteínas terapéuticas mediante vesículas extracelulares para el tratamiento de enfermedades huérfanas

IP: Ibane Abasolo Olaortua
Collaborators: Diego Baranda Martínez-Abasca, Miriam Izquierdo Sans
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding: 59223.42
Reference: FPU20/04210
Duration: 01/12/2021 - 31/03/2025

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Julia Salvador Lodosa

Julia Salvador Lodosa

Read more
Ernest Hidalgo Llompart

Ernest Hidalgo Llompart

Main researcher
Hepato-bilio-pancreatic surgery (HBP) and liver transplantation
Read more
Inmaculada Jimenez Ariza

Inmaculada Jimenez Ariza

Administrative
Accounting and Revenue Unit
Finances Area
Read more
Laura Gonzalez Garcia

Laura Gonzalez Garcia

Growth and Development
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.